WO2003099334A1 - Topically applicable pharmaceutical preparation - Google Patents

Topically applicable pharmaceutical preparation Download PDF

Info

Publication number
WO2003099334A1
WO2003099334A1 PCT/EP2003/005524 EP0305524W WO03099334A1 WO 2003099334 A1 WO2003099334 A1 WO 2003099334A1 EP 0305524 W EP0305524 W EP 0305524W WO 03099334 A1 WO03099334 A1 WO 03099334A1
Authority
WO
WIPO (PCT)
Prior art keywords
roflumilast
salts
pharmaceutical preparation
topical
pde
Prior art date
Application number
PCT/EP2003/005524
Other languages
French (fr)
Inventor
Christina Bolle
Rudolf Linder
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60325354T priority Critical patent/DE60325354D1/en
Priority to KR10-2004-7019272A priority patent/KR20050014844A/en
Priority to NZ536920A priority patent/NZ536920A/en
Priority to EP08166780.0A priority patent/EP2020243B1/en
Priority to UA20041210683A priority patent/UA81910C2/en
Priority to MXPA04011528A priority patent/MXPA04011528A/en
Priority to DK03755048T priority patent/DK1511516T3/en
Priority to NZ537308A priority patent/NZ537308A/en
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Priority to JP2004506857A priority patent/JP5652983B2/en
Priority to CN038124068A priority patent/CN1655823B/en
Priority to AU2003232828A priority patent/AU2003232828B2/en
Priority to US10/515,698 priority patent/US20060084684A1/en
Priority to YUP-1014/04A priority patent/RS51104B/en
Priority to CA2486917A priority patent/CA2486917C/en
Priority to ES03730122T priority patent/ES2354971T3/en
Priority to BR0311339-6A priority patent/BR0311339A/en
Priority to UAA200712909A priority patent/UA88523C2/en
Priority to MEP-854/08A priority patent/ME00565A/en
Priority to EA200401517A priority patent/EA010416B1/en
Priority to EP03755048A priority patent/EP1511516B1/en
Priority to BR0311337-0A priority patent/BR0311337A/en
Priority to KR1020117025130A priority patent/KR101307093B1/en
Priority to SI200331532T priority patent/SI1511516T1/en
Publication of WO2003099334A1 publication Critical patent/WO2003099334A1/en
Priority to IL164935A priority patent/IL164935A/en
Priority to NO20045506A priority patent/NO334882B1/en
Priority to IS7612A priority patent/IS2639B/en
Priority to HRP20041211AA priority patent/HRP20041211B1/en
Priority to HK05111481.8A priority patent/HK1079437A1/en
Priority to US12/149,250 priority patent/US20080280958A1/en
Priority to CY20091100273T priority patent/CY1110312T1/en
Priority to IL209657A priority patent/IL209657A0/en
Priority to US13/219,056 priority patent/US20110313005A1/en
Priority to US14/075,035 priority patent/US20140303215A1/en
Priority to US16/150,759 priority patent/US20190029956A1/en
Priority to CY181101093T priority patent/CY1121133T1/en
Priority to US16/891,823 priority patent/US20210116207A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/12—Crossbows
    • F41B5/123—Compound crossbows
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F41—WEAPONS
    • F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
    • F41B5/00—Bows; Crossbows
    • F41B5/14—Details of bows; Accessories for arc shooting
    • F41B5/1442—Accessories for arc or bow shooting
    • F41B5/1469—Bow-string drawing or releasing devices

Definitions

  • the present invention relates to the field of pharmaceutical technology and describes a topically applicable pharmaceutical preparation comprising as active ingredient a slightly soluble PDE 4 inhibitor.
  • the invention additionally relates to processes for producing the topically applicable pharmaceutical preparation and to the use for the treatment of disorders of the skin, of the eyes and of the airways.
  • PDE 4 inhibitors are currently undergoing advanced clinical testing, including a dosage form for oral administration comprising the active ingredient N-(3,5-di- chloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (INN: roflumilast).
  • WO 95/01338 This and other compounds with a benzamide structure and their use as cyclic nucieotide phosphodiesterase (PDE) inhibitors are described in WO 95/01338. These active ingredients are proposed in WO 95/01338 also for the treatment of certain disorders of the skin (such as, for example, dermatoses). WO 00/53182 proposes the use of roflumilast or its N-oxide for the treatment of multiple sclerosis.
  • PDE cyclic nucieotide phosphodiesterase
  • the active pharmaceutical ingredient for treating disorders of the skin it is desirable to provide the active pharmaceutical ingredient in a pharmaceutical preparation suitable for topical application.
  • a pharmaceutical preparation suitable for topical application As the skilled person is aware, however, the provision of dosage forms for topical application may prove to be extremely difficult or is impossible if the intention is to administer an active ingredient which has a very low solubility.
  • the solubility in water found for the PDE 4 inhibitor N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-di- fluoromethoxybenzamide (INN: roflumilast), which is described in WO 95/01338, is only 0.53 mg/l at 21°C.
  • a first aspect of the invention is therefore a pharmaceutical preparation which can be administered topically and comprises an active pharmaceutical ingredient together with one or more pharmaceutical carriers and/or excipients suitable for topical administration, the active pharmaceutical ingredient being a compound selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof.
  • Roflumilast is the INN for a compound of the formula I
  • R1 is difiuoromethoxy
  • R2 is cyclopropylmethoxy
  • R3 is 3,5-dichloropyrid-4-yl.
  • This compound has the chemical name N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoro- methoxybenzamide (INN: roflumilast).
  • the N-oxide of roflumilast has the chemical name 3-cyclo- propylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl 1-oxide)benzamide.
  • Salts suitable for compounds of the formula I - depending on the substitution - are all acid addition salts but, in particular, all salts with bases. Particular mention may be made of the pharmacologically acceptable salts of the inorganic and organic acids and bases normally used in pharmaceutical technology. Pharmacologically unacceptable salts which, for example, may be the initial products of the process for preparing the compounds of the invention on the industrial scale are converted into pharmacologically acceptable salts by processes known to the skilled worker.
  • water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic acid, methanesulphonic acid, or 3-hydroxy-2-naphthoic acid, the acids — ⁇ *
  • the salts in the equimolar ratio of amounts, or one differing therefrom - depending on whether the acid is monobasic or polybasic and depending on which salt is desired.
  • salts with bases are also particularly suitable.
  • basic salts which may be mentioned are lithium, sodium, potassium, calcium, aluminium, magnesium, titanium, ammonium, me- glumine or guanidinium salts, once again the bases being employed to prepare the salts in the equimolar ratio of amounts or one differing therefrom.
  • the proportion (in per cent by weight based on the weight of the finished pharmaceutical preparation; w/w) of active pharmaceutical ingredient in the pharmaceutical preparation of the invention is usually from 0.001 to 50% by weight.
  • the proportion of active pharmaceutical ingredient is preferably up to 1 % by weight.
  • the topical pharmaceutical preparation of the invention can be produced by processes familiar to the skilled person.
  • the topical pharmaceutical preparation of the invention is a semi- solid dosage form.
  • examples which may be mentioned are, in particular, ointments (e.g. solution ointment, suspension ointment), creams, gels or pastes.
  • Oil-in-water or water-in-oil emulsions are normally referred to as creams.
  • Chiefly used for the oily phase are fatty alcohols, e.g. lauryl, cetyl or stearyl alcohol, fatty acids, e.g. palmitic or stearic acid, liquid or solid paraffins or ozokerite, liquid to solid waxes, e.g. isopropyl myristate, natural or partially synthetic fat, e.g. coconut fatty acid triglyceride, hardened oils, e.g. hydrogenated peanut or castor oil, or fatty acid partial esters of glycerol, e.g. glycerol monostearate or glycerol distearate.
  • fatty alcohols e.g. lauryl, cetyl or stearyl alcohol
  • fatty acids e.g. palmitic or stearic acid
  • liquid or solid paraffins or ozokerite liquid to solid waxes
  • Suitable emulsifiers are surface-active substances, e.g. nonionic surfactants, e.g. fatty acid esters of polyalcohols or ethylene oxide adducts thereof, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid es- ters (Tween®: ICl,) sorbitan fatty acid esters (Span®: ICI), such as, for example, sorbitan oleate and/or sorbitan isostearate, sterols, also polyoxyethylene fatty alcohol ethers or fatty acid esters, or anionic surfactants such as alkali metal salts of fatty alcohol sulphates, e.g.
  • nonionic surfactants e.g. fatty acid esters of polyalcohols or ethylene oxide adducts thereof, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid es- ters (Tween®
  • fatty alcohols e.g. cetyl alcohol or stearyl alcohol.
  • inter alia agents which prevent the cream drying out e.g. polyalcohols such as glycerol, sorbitol, propylene glycol and/or polyethylene glycols, also preservatives, fragrances etc.
  • Ointments may be anhydrous and contain as base the paraffins which are suitable for topical use and are liquid at body temperature, especially low-viscosity paraffin, also the said natural or partially synthetic fats, e.g. coconut fatty acid triglyceride, hardened oils, e.g. hydrogenated peanut or castor oil, fatty acid partial esters of glycerol, e.g. glycerol monostearate and distearate, silicones, e.g. polydi- methylsiloxanes, e.g.
  • hexamethyldisiloxane or octamethyltrisiloxane and, for example, the fatty alcohols mentioned in connection with the hydrous creams and increasing the water uptake capacity, and sterols, wool waxes, other emulsifiers and/or other additives.
  • hydrous, anhydrous and low water-content gels which consist of swellable, gel-forming material.
  • transparent hydrogels based on inorganic or organic macromolecules.
  • acromolecular inorganic components with gel-forming properties are predominantly hydrous or water-absorbing silicates such as aluminium silicates, e.g. bentonite, magnesium-aluminium silicates, e.g. Veegum® - Vanderbilt Exp. Corp., or colloidal silica, e.g. Aerosil® - Degussa.
  • macromolecular organic substances used are natural, semisynthetic or synthetic polymers.
  • Natural and semisynthetic polymers are derived, for example, from polysaccharides with different carbohydrate units, such as cellulose, starch, tragacanth, gum arabic, agar-agar, gelatin, alginic acid and salts thereof, e.g. sodium alginate and derivatives thereof, lower alkylcellulose, for example methyl- or ethylcellulose, carboxy- or hydroxy-lower-alkylcellulose, e.g. carboxymethyl- or hy- droxypropylcellulose.
  • the units of synthetic, gel-forming polymers are, for example, unsaturated, substituted aliphatic compounds such as vinyl alcohol, vinylpyrrolidone, acrylic or methacrylic acid.
  • polymers examples include polyvinyl alcohol derivatives such as Polyviol® - Wacker, polyvi- nylpyrrolidones, such as Kollidon® - BASF or Polyplasdon® - General Aniline, polyacrylates and poly- methacrylates, such as Rohagit S® - Rohm und Haas. It is possible to add conventional additives such as preservatives or fragrances to the gels.
  • polyvinyl alcohol derivatives such as Polyviol® - Wacker, polyvi- nylpyrrolidones, such as Kollidon® - BASF or Polyplasdon® - General Aniline
  • polyacrylates and poly- methacrylates such as Rohagit S® - Rohm und Haas. It is possible to add conventional additives such as preservatives or fragrances to the gels.
  • Pastes are creams or ointments with the constituents mentioned hereinbefore and secretion-absorbing dusting powder constituents such as metal oxides, e.g. titanium oxide or zinc oxide, also talc and/or aluminium silicates, which have the task of binding moisture or secretions.
  • metal oxides e.g. titanium oxide or zinc oxide
  • talc and/or aluminium silicates which have the task of binding moisture or secretions.
  • the topical pharmaceutical preparation of the invention is a semisolid pharmaceutical preparation, with one of the excipients being polyethylene glycol, in particular polyethylene glycol 400.
  • the topicai pharmaceutical preparation of the invention is a transdermal therapeutic system (TTS), for example a system as described in Pharmazeutician Tech- nologie: Moderne Arzneiformen, Academicliche Verlagsgesellschaft mbH Stuttgart 1997, pages 81 et sec.
  • TTSs are characterized in principle by a defined supply of medicinal substance to the skin, a total dose of the medicinal substance in the TTS, a total area and an area which is possibly different therefrom for release of the medicinal substance, a covering sheet (backing layer) which is impermeable to the medicinal substance, a medicinal substance reservoir, a control element which controls the supply of medicinal substance to the skin, a (pressure-sensitive) adhesive layer and a detachable protective layer.
  • TTSs are categorized according to the way the control function is achieved, that is to say how it controls the supply of medicinal substance to the skin. Examples which are mentioned here are TTSs with membrane permeation-controlled release (membrane moderated drug delivery), TTSs with matrix diffusion-controlled release and TTSs with microreservoir solution- controlled release.
  • TTSs with membrane permeation-controlled release are characterized by a polymer membrane composed of a PVA-VA copolymer (Chronomer®) which controls the permeation of the medicinal substance from the reservoir into the skin.
  • the medicinal substance is initially in the form of solid particles or as a dispersion or solution in the reservoir.
  • the polymer membrane can be attached to the reservoir in various ways (extrusion, encapsulation, microencapsulation).
  • TTSs with matrix diffusion-controlled release have a comparatively simpler structure. They contain no separate control element.
  • the release of medicinal substance is controlled by a lipophilic or hydrophilic polymer matrix and/or the adhesive layer.
  • TTSs with a matrix in gel form TTSs which represent solid polymer laminates.
  • the medicinal substance reservoir is formed by the medicinal substance dissolved in the matrix (monolithic system) or a homogeneous dispersion of solid medicinal substance particles.
  • a matrix TTS can be produced by mixing the medicinal substance particles with a viscous liquid or semisolid polymer at room temperature, followed by crosslinking the polymer chains.
  • a further possibility is also to mix the medicinal substance at elevated temperature with softened polymer (hot melt technique), or the two components (dissolved in an organic solvent) are mixed together and the solvent is then removed in vacuo (solvent evaporation).
  • Shaping is possible by pouring into suitable moulds, spreading with special devices (knives) or by extrusion.
  • TTSs with microreservoir solution-controlled release (microsealed drug delivery, MDD principle)
  • numerous microcompartments containing the active ingredient and 10-200 ⁇ m in size are embedded in a matrix which represents both reservoir and delivery-control element. Because of the matrix, these TTSs are actually assigned to the matrix systems.
  • the medicinal substance is initially dispersed together with water and 40% polyethylene glycol 400 in isopropyl palmitate, which acts as permeation promoter.
  • the resulting dispersion is incorporated by using a special high- energy dispersion technique into a viscous silicone elastomer which simultaneously undergoes catalytic polymerization.
  • the medicinal substance-containing matrix can be shaped specifically by melt or extrusion techniques before it is combined with the carrier in the manner already described. Depending on the physicochemical properties of the medicinal substances and the intended liberation, it is possible to cover the matrix with a layer of a biocompatible polymer in order thus to modify the mechanism and the rate of liberation.
  • the topical pharmaceutical preparation of the invention is a dosage form for use on the eye (ophthalmologicals).
  • eyebaths or eye lotions examples which may be mentioned in this connection are eyebaths or eye lotions, eye inserts, eye ointments, eye sprays, eye drops, preparations for intraocular injection and eyelid ointments.
  • the dosage form of the invention is an eye ointment or eye drops.
  • Eye drops preferably comprise according to the invention aqueous or oily suspensions of the active ingredient. It is preferred in this connection for the particle size of the active ingredient employed to be 90% less than 10 ⁇ m.
  • suspension stabilizers such as, for example, substituted celluloses (e.g. methylcellulose, hydroxypropylmethylcellulose), polyvinyl alcohol, polyvi- nylpyrrolidone, in addition to preservatives (e.g. chlorocresol, phenylmercury compounds, phenyletha- nol, benzalkonium chloride or mixtures of individual components) and, where appropriate, sodium chloride to adjust to isotonicity.
  • preservatives e.g. chlorocresol, phenylmercury compounds, phenyletha- nol, benzalkonium chloride or mixtures of individual components
  • sodium chloride to adjust to isotonicity
  • oily eye drops are castor oil, peanut oil or medium chain length triglycerides.
  • ointment bases which have the following properties: sterility or extremely low microbe content, non-irritating, good activity, good distribution of the active ingredient or its solution in the ointment, suppleness, rapid dispersion as fine film over the eyeball, good adhesion to the eye, good stability and low impairment of vision.
  • Hydrocarbon- or cholesterol-containing bases will therefore preferably be employed according to the invention for eye ointments.
  • liquid paraffin is preferably added for consistency reasons. To achieve good spreading, it is preferred according to the invention to provide compositions of limited viscosity.
  • the viscosity at 32°C is preferably below 1 000 mPa.s, and the yield point is preferably below 300 mPa.
  • 90% of the active ingredient particles it is preferred according to the invention for 90% of the active ingredient particles to be below 10 ⁇ m, and no particles above 90 ⁇ m should occur.
  • preservatives such as benzalkonium chloride, thiomersal or phenylethyl alcohol. Examples
  • Production takes place by dissolving the active ingredient in the stated amount of polyethylene glycol at about 60-70°C. About 90 grams of purified water are added and mixed homogeneously, and the Carbopol 934 is homogeneously dispersed therein with a high-speed stirrer. While stirring slowly, sodium hydroxide solution is added until a pH of 6.5-7.5 is reached. The remaining water is added up to the final weight and homogeneously mixed.
  • Production takes place by treating the two polyethylene glycois to 70°C to give a clear melt.
  • the active ingredient is added likewise to give a clear solution.
  • the preparation is cooled to room temperature while stirring slowly.
  • Production takes place by making a clear solution of the neutral oil, the cetostearyl alcohol and Tego Care 150 at about 70°C.
  • the polyethylene glycol, in which the roflumilast has been dissolved, is likewise stirred in using a high-speed stirrer.
  • the water heated to 70°C is added to the lipid phase.
  • a Tur- rax is used for homogenization.
  • the preparation is then stirred until cold (room temperature).
  • Cremophor A6® (BASF) 4.00 g
  • Production takes place by heating all the components (apart from water) together to about 70-80°C to give a clear solution. The water is then added while stirring, and the preparation produced in this way is cooled to room temperature while stirring.
  • Cremophor A6® (BASF) 2.00 g
  • Cremophor A6® (BASF) 4.00 g
  • composition of an eye ointment (quantity for 1 000 grams)
  • White petrolatum 795 g Production A clear melt of the cetyl alcohol, the high-viscosity paraffin and the white petrolatum is prepared at about 70°C. The micronized roflumilast (90% of the particles below 10 ⁇ m) is stirred in, and a homogeneous dispersion is prepared using an Ultra-Turrax. The suspension is cooled to room temperature while stirring and used to fill suitable tubes.
  • composition of a drop solution in the form of an emulsion (quantity for 1 000 millilitres)
  • composition of a nose ointment (quantity for 1 000 grams)
  • a clear melt of the cetyl alcohol, the high-viscosity paraffin, the wool wax and the white petrolatum is prepared at about 70°C.
  • the micronized roflumilast (90% of the particles below 10 ⁇ m) is stirred in, and a homogeneous dispersion is prepared using an Ultra-Turrax.
  • the suspension is cooled to room temperature while stirring and used to fill suitable tubes. Investigations of the pharmacokinetics of the topical pharmaceutical preparations
  • Example 7 A preparation corresponding to Example 7 and a preparation corresponding to Example 8 containing [ 4 C]roflumilast were applied to shaven areas of rat skin (5 male Wistar rats) 4 cm 2 in size.
  • Example 7 Cmax: 0.214 mg equiv./l, AUC(0-24 h): 4.13 (mg equiv./l x h)
  • Example 8 Cmax: 0.214 mg equiv./l, AUC(0-24 h): 3.99 (mg equiv./l x h)
  • Example 7 Cmax: 0.126, AUC: 2.43
  • Example 8 Cmax: 0.126, AUC: 2.35
  • the ratio of the AUC (preparation of Example 7) to the AUC (oral) is 78% and that of the AUC (preparation of Example 8) to the AUC (oral) is 76%.
  • Example 5 A preparation corresponding to Example 5 containing [ 14 C]roflumilast was applied to a shaven area of rat skin (male Wistar rat) 4 cm 2 in size.
  • the dose was 1.77 mg/kg.
  • Example 5 Cmax: 0.331 mg equiv./l, AUC(0-24 h): 4.99 (mg equiv./l x h)
  • the dosage forms of the invention can be employed for the treatment and prevention of all diseases regarded as treatable or preventable through the use of PDE 4 inhibitors.
  • Selective cyclic nucieotide phosphodiesterase (PDE) inhibitors are suitable on the one hand as bronchial therapeutic agents (for the treatment of airway obstructions owing to their dilating effect but also owing to their effect increasing the respiratory rate and respiratory drive) and for eliminating erectile dysfunction owing to the vasodilating effect, but on the other hand especially for the treatment of disorders, especially of an inflammatory nature, e.g.
  • mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma-interferon, tumor necrosis factor (TNF) or oxygen free radicals and proteases.
  • mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma-interferon, tumor necrosis factor (TNF) or oxygen free radicals and proteases.
  • mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma-interferon
  • the pharmaceutical preparations of the invention can therefore be used in human and veterinary medicine for example for the treatment and prophylaxis of the following diseases: acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD); dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vul- garis), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders; disorders based on excessive release of T
  • disorders of the arthritic type rheumatoid arthritis, rheumatoid spondylitis, osteoarthri- tis and other arthritic states
  • disorders of the immune system AIDS, multiple sclerosis
  • types of shock septic shock, endotoxin shock, gram-negative sepsis, toxic shock syndrome and ARDS (adult respiratory distress syndrome)] and generalized inflammations in the gastrointestinal region (Crohn's disease and ulcerative colitis
  • the pharmaceutical preparations of the invention are particularly suitable for the treatment of disorders of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders. Mention may preferably be made of the use of the pharmaceutical preparations of the invention in the treatment of psoriasis and atopic eczema.
  • the invention therefore also relates further to the use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the treatment of disorders of the skin which are regarded as treatable or preventable by application of PDE 4 inhibitors.
  • dermatoses especially of a proliferative, inflammatory and allergic nature
  • dermatoses especially of a proliferative, inflammatory and allergic nature
  • psoriasis vulgaris
  • toxic and allergic contact eczema atopic eczema
  • seborrhoeic eczema lichen simplex
  • sunburn pruritus in the genitoanal region
  • alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas
  • endogenous and exogenous acne acne rosacea and other proliferative, inflammatory and allergic skin disorders.
  • the invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases.
  • the method is characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disease, with the active pharmaceutical ingredient being administered in a topical pharmaceutical preparation of the invention.
  • the disease is preferably a disorder of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders.
  • the method is characterized in that the administration takes place by dermal administration, i.e. through application of the topical pharmaceutical preparations of the invention to the skin or mucous membranes.
  • the invention relates to the treatment of mammals, including humans, suffering from an eye disorder which is regarded as treatable or preventable through the use of PDE4 inhibitors.
  • This eye disorder is preferably selected from the group of allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation, inflammation of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glaucoma, retinal oedema, retinitis pigmentosa and diabetic retinopathy.
  • the eye disorder is preferably allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation or uveitis.
  • the method is characterized in that the administration takes place by application of the preparation of the invention to the eye.
  • the invention therefore also relates further to the use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the systemic treatment of diseases regarded as treatable or preventable by application of PDE 4 inhibitors.
  • Mention may preferably be made in this connection of acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondy- litis, osteoarthritis and other arthritic states).
  • the pharmaceutical preparations of the invention are moreover particularly suitable for adminstration to groups of patients who are suffering from the abovementioned diseases and have problems in taking pharmaceutical preparations to be administered orally, such as, for example, bedridden patients, patients in intensive medical care, patients with swallowing difficulties and children.
  • the invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases.
  • the method is characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disease, with the active pharmaceutical ingredient being administered in a topical pharmaceutical preparation of the invention.
  • the disease is preferably acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states).
  • the method is characterized in that administration takes place by dermal administration, i.e. through application of the topical pharmaceutical preparations of the invention to the skin or mucous membranes.
  • the dosage forms of the invention comprise the active pharmaceutical ingredient in the dose customary for the treatment of the particular disease.
  • the dosage of the active ingredient is of the order of magnitude customary for PDE inhibitors, it being possible to administer the daily dose in one or more dosage units.
  • Customary dosages are disclosed for example in WO 95/01338.
  • the normal dose on systemic therapy (oral) is between 0.001 and 3 mg per kilogram and day.
  • Dosage forms preferred according to the invention for topical administration contain from 0.005 mg to 5 mg of roflumilast, preferably from 0.01 mg to 2.5 mg, particularly preferably 0.1 mg to 0.5 mg of roflumilast per dosage unit.
  • Examples of pharmaceutical preparations of the invention contain 0.01 mg, 0.1 mg, 0.125 mg, 0.25 mg and 0.5 mg of roflumilast per dosage unit.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A topical pharmaceutical preparation for administering a slightly soluble PDE 4 inhibitor is described. A surprisingly good systemic bioavailability is observed with this dosage form.

Description

Topically applicable pharmaceutical preparation
Technical field
The present invention relates to the field of pharmaceutical technology and describes a topically applicable pharmaceutical preparation comprising as active ingredient a slightly soluble PDE 4 inhibitor. The invention additionally relates to processes for producing the topically applicable pharmaceutical preparation and to the use for the treatment of disorders of the skin, of the eyes and of the airways.
Prior art
Cyclic nucieotide phosphodiesterase (PDE) inhibitors (specifically of type 4) are currently of special interest as a new generation of active ingredients for treating inflammatory disorders, especially disorders of the airways such as asthma or airway obstructions (such as, for example, COPD = chronic obstructive pulmonary disease). A number of PDE 4 inhibitors are currently undergoing advanced clinical testing, including a dosage form for oral administration comprising the active ingredient N-(3,5-di- chloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide (INN: roflumilast). This and other compounds with a benzamide structure and their use as cyclic nucieotide phosphodiesterase (PDE) inhibitors are described in WO 95/01338. These active ingredients are proposed in WO 95/01338 also for the treatment of certain disorders of the skin (such as, for example, dermatoses). WO 00/53182 proposes the use of roflumilast or its N-oxide for the treatment of multiple sclerosis.
For treating disorders of the skin it is desirable to provide the active pharmaceutical ingredient in a pharmaceutical preparation suitable for topical application. As the skilled person is aware, however, the provision of dosage forms for topical application may prove to be extremely difficult or is impossible if the intention is to administer an active ingredient which has a very low solubility. Thus, for example, the solubility in water found for the PDE 4 inhibitor N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-di- fluoromethoxybenzamide (INN: roflumilast), which is described in WO 95/01338, is only 0.53 mg/l at 21°C.
Description of the invention
It has now been found, surprisingly, that topically applicable pharmaceutical preparations comprising the slightly soluble PDE 4 inhibitor roflumilast show a very good effect in the treatment of dermatoses on local, dermal application. Also found, entirely surprisingly, besides the local effect, is an excellent systemic effect which is comparable with that of an oral dosage form. A first aspect of the invention is therefore a pharmaceutical preparation which can be administered topically and comprises an active pharmaceutical ingredient together with one or more pharmaceutical carriers and/or excipients suitable for topical administration, the active pharmaceutical ingredient being a compound selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof.
Roflumilast is the INN for a compound of the formula I
Figure imgf000003_0001
in which
R1 is difiuoromethoxy,
R2 is cyclopropylmethoxy and
R3 is 3,5-dichloropyrid-4-yl.
This compound has the chemical name N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoro- methoxybenzamide (INN: roflumilast). The N-oxide of roflumilast has the chemical name 3-cyclo- propylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl 1-oxide)benzamide.
This compound of the formula I, its salts, the N-oxide, its salts and the use of these compounds as phosphodiesterase (PDE) 4 inhibitors are described in the international patent application WO 95/01338.
Salts suitable for compounds of the formula I - depending on the substitution - are all acid addition salts but, in particular, all salts with bases. Particular mention may be made of the pharmacologically acceptable salts of the inorganic and organic acids and bases normally used in pharmaceutical technology. Pharmacologically unacceptable salts which, for example, may be the initial products of the process for preparing the compounds of the invention on the industrial scale are converted into pharmacologically acceptable salts by processes known to the skilled worker. Those suitable on the one hand are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic acid, methanesulphonic acid, or 3-hydroxy-2-naphthoic acid, the acids — ■*
being employed to prepare the salts in the equimolar ratio of amounts, or one differing therefrom - depending on whether the acid is monobasic or polybasic and depending on which salt is desired.
On the other hand, salts with bases are also particularly suitable. Examples of basic salts which may be mentioned are lithium, sodium, potassium, calcium, aluminium, magnesium, titanium, ammonium, me- glumine or guanidinium salts, once again the bases being employed to prepare the salts in the equimolar ratio of amounts or one differing therefrom.
The proportion (in per cent by weight based on the weight of the finished pharmaceutical preparation; w/w) of active pharmaceutical ingredient in the pharmaceutical preparation of the invention is usually from 0.001 to 50% by weight. The proportion of active pharmaceutical ingredient is preferably up to 1 % by weight.
The pharmaceutical carriers and/or excipients suitable for topical administration are preferably according to the invention conventional carriers and/or excipients known to the skilled person in connection with pharmaceutical preparations for dermal administration (= dermatologicals). Examples which may be mentioned are carriers and/or excipients which are suitable for producing dusting powders, emulsions, suspensions, sprays, oils, ointments, greasy ointments, creams, pastes, gels, foams or solutions, and transdermal therapeutic systems.
The topical pharmaceutical preparation of the invention can be produced by processes familiar to the skilled person.
Conventional dermatologicals and their production, and preferred carriers and/or excipients for the individual pharmaceutical preparations are described, for example, in the textbook "Pharmazeutische Technologie" (Sucker, Fuchs, Speiser, Georg Thieme Verlag,1978 from page 629).
In a first embodiment of the invention, the topical pharmaceutical preparation of the invention is a semi- solid dosage form. Examples which may be mentioned are, in particular, ointments (e.g. solution ointment, suspension ointment), creams, gels or pastes.
Oil-in-water or water-in-oil emulsions are normally referred to as creams. Chiefly used for the oily phase are fatty alcohols, e.g. lauryl, cetyl or stearyl alcohol, fatty acids, e.g. palmitic or stearic acid, liquid or solid paraffins or ozokerite, liquid to solid waxes, e.g. isopropyl myristate, natural or partially synthetic fat, e.g. coconut fatty acid triglyceride, hardened oils, e.g. hydrogenated peanut or castor oil, or fatty acid partial esters of glycerol, e.g. glycerol monostearate or glycerol distearate. Suitable emulsifiers are surface-active substances, e.g. nonionic surfactants, e.g. fatty acid esters of polyalcohols or ethylene oxide adducts thereof, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid es- ters (Tween®: ICl,) sorbitan fatty acid esters (Span®: ICI), such as, for example, sorbitan oleate and/or sorbitan isostearate, sterols, also polyoxyethylene fatty alcohol ethers or fatty acid esters, or anionic surfactants such as alkali metal salts of fatty alcohol sulphates, e.g. sodium lauryi sulphate, sodium cetyl sulphate or sodium stearyl sulphate, which are normally used in the presence of said fatty alcohols, e.g. cetyl alcohol or stearyl alcohol. It is possible to add to the aqueous phase inter alia agents which prevent the cream drying out, e.g. polyalcohols such as glycerol, sorbitol, propylene glycol and/or polyethylene glycols, also preservatives, fragrances etc.
Ointments may be anhydrous and contain as base the paraffins which are suitable for topical use and are liquid at body temperature, especially low-viscosity paraffin, also the said natural or partially synthetic fats, e.g. coconut fatty acid triglyceride, hardened oils, e.g. hydrogenated peanut or castor oil, fatty acid partial esters of glycerol, e.g. glycerol monostearate and distearate, silicones, e.g. polydi- methylsiloxanes, e.g. hexamethyldisiloxane or octamethyltrisiloxane, and, for example, the fatty alcohols mentioned in connection with the hydrous creams and increasing the water uptake capacity, and sterols, wool waxes, other emulsifiers and/or other additives.
In the case of gels, a distinction is made between hydrous, anhydrous and low water-content gels, which consist of swellable, gel-forming material. Chiefly suitable are transparent hydrogels based on inorganic or organic macromolecules. acromolecular inorganic components with gel-forming properties are predominantly hydrous or water-absorbing silicates such as aluminium silicates, e.g. bentonite, magnesium-aluminium silicates, e.g. Veegum® - Vanderbilt Exp. Corp., or colloidal silica, e.g. Aerosil® - Degussa. Examples of macromolecular organic substances used are natural, semisynthetic or synthetic polymers. Natural and semisynthetic polymers are derived, for example, from polysaccharides with different carbohydrate units, such as cellulose, starch, tragacanth, gum arabic, agar-agar, gelatin, alginic acid and salts thereof, e.g. sodium alginate and derivatives thereof, lower alkylcellulose, for example methyl- or ethylcellulose, carboxy- or hydroxy-lower-alkylcellulose, e.g. carboxymethyl- or hy- droxypropylcellulose. The units of synthetic, gel-forming polymers are, for example, unsaturated, substituted aliphatic compounds such as vinyl alcohol, vinylpyrrolidone, acrylic or methacrylic acid. Examples to be mentioned of such polymers are polyvinyl alcohol derivatives such as Polyviol® - Wacker, polyvi- nylpyrrolidones, such as Kollidon® - BASF or Polyplasdon® - General Aniline, polyacrylates and poly- methacrylates, such as Rohagit S® - Rohm und Haas. It is possible to add conventional additives such as preservatives or fragrances to the gels.
Pastes are creams or ointments with the constituents mentioned hereinbefore and secretion-absorbing dusting powder constituents such as metal oxides, e.g. titanium oxide or zinc oxide, also talc and/or aluminium silicates, which have the task of binding moisture or secretions.
In a preferred embodiment of the invention, the topical pharmaceutical preparation of the invention is a semisolid pharmaceutical preparation, with one of the excipients being polyethylene glycol, in particular polyethylene glycol 400.
In a further embodiment of the invention, the topicai pharmaceutical preparation of the invention is a transdermal therapeutic system (TTS), for example a system as described in Pharmazeutische Tech- nologie: Moderne Arzneiformen, Wissenschaftliche Verlagsgesellschaft mbH Stuttgart 1997, pages 81 et sec. TTSs are characterized in principle by a defined supply of medicinal substance to the skin, a total dose of the medicinal substance in the TTS, a total area and an area which is possibly different therefrom for release of the medicinal substance, a covering sheet (backing layer) which is impermeable to the medicinal substance, a medicinal substance reservoir, a control element which controls the supply of medicinal substance to the skin, a (pressure-sensitive) adhesive layer and a detachable protective layer. It is possible on occasions for more than one function to be fulfilled by one and the same element, e.g. reservoir, control and adhesive functions by a suitable adhesive matrix. From the viewpoint of pharmaceutical technology, TTSs are categorized according to the way the control function is achieved, that is to say how it controls the supply of medicinal substance to the skin. Examples which are mentioned here are TTSs with membrane permeation-controlled release (membrane moderated drug delivery), TTSs with matrix diffusion-controlled release and TTSs with microreservoir solution- controlled release.
TTSs with membrane permeation-controlled release are characterized by a polymer membrane composed of a PVA-VA copolymer (Chronomer®) which controls the permeation of the medicinal substance from the reservoir into the skin. The medicinal substance is initially in the form of solid particles or as a dispersion or solution in the reservoir. The polymer membrane can be attached to the reservoir in various ways (extrusion, encapsulation, microencapsulation). TTSs with matrix diffusion-controlled release have a comparatively simpler structure. They contain no separate control element. The release of medicinal substance is controlled by a lipophilic or hydrophilic polymer matrix and/or the adhesive layer. It is possible to distinguish, according to the characteristics of the matrix, between TTSs with a matrix in gel form and TTSs which represent solid polymer laminates. The medicinal substance reservoir is formed by the medicinal substance dissolved in the matrix (monolithic system) or a homogeneous dispersion of solid medicinal substance particles. A matrix TTS can be produced by mixing the medicinal substance particles with a viscous liquid or semisolid polymer at room temperature, followed by crosslinking the polymer chains. A further possibility is also to mix the medicinal substance at elevated temperature with softened polymer (hot melt technique), or the two components (dissolved in an organic solvent) are mixed together and the solvent is then removed in vacuo (solvent evaporation). Shaping is possible by pouring into suitable moulds, spreading with special devices (knives) or by extrusion. In the case of TTSs with microreservoir solution-controlled release (microsealed drug delivery, MDD principle), numerous microcompartments containing the active ingredient and 10-200 μm in size are embedded in a matrix which represents both reservoir and delivery-control element. Because of the matrix, these TTSs are actually assigned to the matrix systems. For production, the medicinal substance is initially dispersed together with water and 40% polyethylene glycol 400 in isopropyl palmitate, which acts as permeation promoter. The resulting dispersion is incorporated by using a special high- energy dispersion technique into a viscous silicone elastomer which simultaneously undergoes catalytic polymerization. The medicinal substance-containing matrix can be shaped specifically by melt or extrusion techniques before it is combined with the carrier in the manner already described. Depending on the physicochemical properties of the medicinal substances and the intended liberation, it is possible to cover the matrix with a layer of a biocompatible polymer in order thus to modify the mechanism and the rate of liberation.
In another embodiment of the invention, the topical pharmaceutical preparation of the invention is a dosage form for use on the eye (ophthalmologicals). Examples which may be mentioned in this connection are eyebaths or eye lotions, eye inserts, eye ointments, eye sprays, eye drops, preparations for intraocular injection and eyelid ointments. In a preferred embodiment, the dosage form of the invention is an eye ointment or eye drops. Eye drops preferably comprise according to the invention aqueous or oily suspensions of the active ingredient. It is preferred in this connection for the particle size of the active ingredient employed to be 90% less than 10 μm.
Preferably used in the case of aqueous suspensions are suspension stabilizers such as, for example, substituted celluloses (e.g. methylcellulose, hydroxypropylmethylcellulose), polyvinyl alcohol, polyvi- nylpyrrolidone, in addition to preservatives (e.g. chlorocresol, phenylmercury compounds, phenyletha- nol, benzalkonium chloride or mixtures of individual components) and, where appropriate, sodium chloride to adjust to isotonicity. Preferably employed according to the invention in the case of oily eye drops are castor oil, peanut oil or medium chain length triglycerides. It is possible in the case of eye ointments to use according to the invention ointment bases which have the following properties: sterility or extremely low microbe content, non-irritating, good activity, good distribution of the active ingredient or its solution in the ointment, suppleness, rapid dispersion as fine film over the eyeball, good adhesion to the eye, good stability and low impairment of vision. Hydrocarbon- or cholesterol-containing bases will therefore preferably be employed according to the invention for eye ointments. In the case of petrolatum, liquid paraffin is preferably added for consistency reasons. To achieve good spreading, it is preferred according to the invention to provide compositions of limited viscosity. The viscosity at 32°C is preferably below 1 000 mPa.s, and the yield point is preferably below 300 mPa. In the case of suspension ointments it is preferred according to the invention for 90% of the active ingredient particles to be below 10 μm, and no particles above 90 μm should occur. In the case of water/oil emulsion ointments, it is preferred according to the invention to add preservatives such as benzalkonium chloride, thiomersal or phenylethyl alcohol. Examples
Production of the dosage forms of the invention
Example 1
550 grams contain
Polyethylene glycol 400 440.00 g
Carbopol 934® 8.25 g
Roflumilast 1.375 g
Sodium hydroxide solution q.s.
Purified water to 550.00 g
Production takes place by dissolving the active ingredient in the stated amount of polyethylene glycol at about 60-70°C. About 90 grams of purified water are added and mixed homogeneously, and the Carbopol 934 is homogeneously dispersed therein with a high-speed stirrer. While stirring slowly, sodium hydroxide solution is added until a pH of 6.5-7.5 is reached. The remaining water is added up to the final weight and homogeneously mixed.
Example 2
550 grams contain
Roflumilast 1.65 g
Polyethylene glycol 400 440.00 g
Polyethylene glycol 4000 to 550.0 g
Production takes place by treating the two polyethylene glycois to 70°C to give a clear melt. The active ingredient is added likewise to give a clear solution. The preparation is cooled to room temperature while stirring slowly.
Example 3
550 grams contain
Roflumilast 1.10 g
Tego Care 150® 27.50 g
(Th. Goldschmidt)
Neutral oil (Miglyol 812®) 137.50 g Polyethylene glycol 400 275.00 g
Cetostearyl alcohol 11.00 g
Purified water to 550 g
Production takes place by making a clear solution of the neutral oil, the cetostearyl alcohol and Tego Care 150 at about 70°C. The polyethylene glycol, in which the roflumilast has been dissolved, is likewise stirred in using a high-speed stirrer. The water heated to 70°C is added to the lipid phase. A Tur- rax is used for homogenization. The preparation is then stirred until cold (room temperature).
Example 4
100 grams contain
Roflumilast 0.25 g
Neutral oil (Miglyol 812®) 16.00 g
Glycerol monostearate 8.00 g
Cremophor A6® (BASF) 4.00 g
Polyethylene glycol 400 62.50 g
Purified water to 100.00 g
Production takes place by heating all the components (apart from water) together to about 70-80°C to give a clear solution. The water is then added while stirring, and the preparation produced in this way is cooled to room temperature while stirring.
Example 5
100 grams contain
Roflumilast 0.25 g
Liquid paraffin 15.00 g
Wool wax 5.00 g
White petrolatum to 100 g
Production takes place by making a clear melt of the liquid paraffin, the wool wax and the white petrolatum at about 80°C. The micronized active ingredient is added, and the preparation is stirred until it has cooled to room temperature. Example 6
Roflumilast 0.10 g
Liquid paraffin 10.00 g
Wool wax 5.00 g
White petrolatum to 100 g
Production takes place in analogy to Example 5.
Example 7
Roflumilast 0.10 g
Neutral oil (Miglyol 812®) 16.00 g
Glycerol monostearate 8.00 g
Cremophor A6® (BASF) 2.00 g
Polyethylene glycol 400 62.50 g
Purified water to 100.00 g
Production takes place in analogy to Example 4.
Example 8
Roflumilast 0.10 g
Neutral oil ( Miglyol 812®) 16.00 g
Glycerol monostearate 8.00 g
Cremophor A6® (BASF) 4.00 g
Polyethylene glycol 400 62.50 g
Purified water to 100.00 g
Production takes place in analogy to Example 4.
Example 9
Composition of an eye ointment (quantity for 1 000 grams)
Roflumilast 1 9
Cetyl alcohol 4 g
High-viscosity paraffin 200 g
White petrolatum 795 g Production: A clear melt of the cetyl alcohol, the high-viscosity paraffin and the white petrolatum is prepared at about 70°C. The micronized roflumilast (90% of the particles below 10 μm) is stirred in, and a homogeneous dispersion is prepared using an Ultra-Turrax. The suspension is cooled to room temperature while stirring and used to fill suitable tubes.
Example 10
Composition of a drop solution in the form of an emulsion (quantity for 1 000 millilitres)
Roflumilast 1.5 g
Medium chain length triglycerides 100.0 g
Lecithin 12.0 g
Glycerol 25.0 g
Thiomersal 0.1 g
Purified water to 1 000 ml
Production: First the roflumilast and then the lecithin are dissolved in the medium chain length triglycerides and the glycerol at 30°C-40°C. While stirring vigorously, the purified water is added and then homogenized until the droplet size of the disperse phase is below 500 nm. The thiomersal is dissolved by stirring. The emulsion is filtered through a 0.45 μm filter and dispensed into suitable containers.
Example 11
Composition of a nose ointment (quantity for 1 000 grams)
Roflumilast 1 g
Cetyl alcohol 4 g
Wool wax 50 g
High-viscosity paraffin 200 g
White petrolatum 745 g
Production: A clear melt of the cetyl alcohol, the high-viscosity paraffin, the wool wax and the white petrolatum is prepared at about 70°C. The micronized roflumilast (90% of the particles below 10 μm) is stirred in, and a homogeneous dispersion is prepared using an Ultra-Turrax. The suspension is cooled to room temperature while stirring and used to fill suitable tubes. Investigations of the pharmacokinetics of the topical pharmaceutical preparations
Comparison of pharmacokinetics parameters of topical pharmaceutical preparations of the invention with oral form
Example A
A preparation corresponding to Example 7 and a preparation corresponding to Example 8 containing [ 4C]roflumilast were applied to shaven areas of rat skin (5 male Wistar rats) 4 cm2 in size. The radioactivity concentrations were measured in the plasma after 1 h, 4 h, 8 h, 24 h and in the urine (0-24 h) (n = 5). The dose was 1.7 mg/kg.
Results:
Preparation of Example 7: Cmax: 0.214 mg equiv./l, AUC(0-24 h): 4.13 (mg equiv./l x h) Preparation of Example 8: Cmax: 0.214 mg equiv./l, AUC(0-24 h): 3.99 (mg equiv./l x h)
The results standardized to 1 mg/kg are
Preparation of Example 7: Cmax: 0.126, AUC: 2.43 Preparation of Example 8: Cmax: 0.126, AUC: 2.35
Comparison with kinetic parameters after oral administration of 1 mg/kg: Cmax: 0.225 mg equivVI, AUC(0-24 h): 3.10 (mg equiv./l x h)
The ratio of the AUC (preparation of Example 7) to the AUC (oral) is 78% and that of the AUC (preparation of Example 8) to the AUC (oral) is 76%.
Results of comparison of the excretions with the urine: Preparation of Example 7: 19.4% of the dose Preparation of Example 8: 18.0% of the dose Oral administration: 18.4% of the dose
Conclusion:
After percutaneous administration of 1.7 mg/kg [14C]roflumilast to rats, the total radioactivity is transported well through the skin and reaches a maximum plasma level of 0.214 mg equiv./l after 4 h, irrespective of the preparation employed. Based on the total radioactivity, the AUCs and the excretions with the urine after percutaneous administration are negligibly different from those after oral administration. _ ^ _
Example B
A preparation corresponding to Example 5 containing [14C]roflumilast was applied to a shaven area of rat skin (male Wistar rat) 4 cm2 in size. The radioactivity concentrations were measured in the plasma after 1 h, 4 h, 8 h, 24 h and in the urine (0-24 h) (n = 5). The dose was 1.77 mg/kg.
Preparation of Example 5: Cmax: 0.331 mg equiv./l, AUC(0-24 h): 4.99 (mg equiv./l x h)
The results standardized to 1 mg/kg are
Preparation of Example 5: Cmax: 0.187, AUC: 2.82
Comparison with kinetic parameters after oral administration of 1 mg/kg: Cmax: 0.225 mg equiv./l, AUC(0-24 h): 3.10 (mg equiv./l x h)
Results of comparison of the excretions with the urine: Preparation of Example 5: 22.0% of the dose Oral administration: 18.4% of the dose
Conclusion:
These data show that roflumilast is absorbed from the preparation of Example 5 even somewhat better than from the preparations corresponding to Example 7 or 8. The excretion with the urine in the 24 h after administration is 22%, which is also in the region of the excretion with the urine after dermal administration of the preparations corresponding to Example 7 or 8. Comparison with oral administration shows that, irrespective of the composition of the topical preparation, similar Cmax and AUCs and similar excretions with the urine are achieved.
Industrial applicability
The dosage forms of the invention can be employed for the treatment and prevention of all diseases regarded as treatable or preventable through the use of PDE 4 inhibitors. Selective cyclic nucieotide phosphodiesterase (PDE) inhibitors (specifically of type 4) are suitable on the one hand as bronchial therapeutic agents (for the treatment of airway obstructions owing to their dilating effect but also owing to their effect increasing the respiratory rate and respiratory drive) and for eliminating erectile dysfunction owing to the vasodilating effect, but on the other hand especially for the treatment of disorders, especially of an inflammatory nature, e.g. of the airways (asthma prophylaxis), of the skin, of the central nervous system, of the intestine, of the eyes and of the joints, which are promoted by mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma-interferon, tumor necrosis factor (TNF) or oxygen free radicals and proteases. The pharmaceutical preparations of the invention can therefore be used in human and veterinary medicine for example for the treatment and prophylaxis of the following diseases: acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD); dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vul- garis), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders; disorders based on excessive release of TNF and leukotrienes, e.g. disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthri- tis and other arthritic states), disorders of the immune system (AIDS, multiple sclerosis), types of shock [septic shock, endotoxin shock, gram-negative sepsis, toxic shock syndrome and ARDS (adult respiratory distress syndrome)] and generalized inflammations in the gastrointestinal region (Crohn's disease and ulcerative colitis); disorders based on allergic and/or chronic abnormal immunological reactions in the region of the upper airways (pharyngeal space, nose) and adjacent regions (paranasal sinuses, eyes), such as, for example, allergic rhinitis/sinusitis, chronic rhinitis/sinusitis, allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular iens implantation, inflammation of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glaucoma, retinal oedema, retinitis pigmentosa, diabetic retinopathy, and nasal polyps; but also cardiac disorders which can be treated by PDE inhibitors, such as, for example, heart failure, or disorders which can be treated owing to the tissue-relaxant effect of PDE inhibitors, such as, for example, erectile dysfunction or colic of the kidneys and ureters connected with kidney stones; or else disorders of the CNS such as, for example, depressions or arteriosclerotic dementia.
The pharmaceutical preparations of the invention are particularly suitable for the treatment of disorders of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders. Mention may preferably be made of the use of the pharmaceutical preparations of the invention in the treatment of psoriasis and atopic eczema.
The invention therefore also relates further to the use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the treatment of disorders of the skin which are regarded as treatable or preventable by application of PDE 4 inhibitors. Mention may preferably be made in this connection of dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders.
The invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases. The method is characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disease, with the active pharmaceutical ingredient being administered in a topical pharmaceutical preparation of the invention. The disease is preferably a disorder of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders. The method is characterized in that the administration takes place by dermal administration, i.e. through application of the topical pharmaceutical preparations of the invention to the skin or mucous membranes.
In another preferred embodiment, the invention relates to the treatment of mammals, including humans, suffering from an eye disorder which is regarded as treatable or preventable through the use of PDE4 inhibitors. This eye disorder is preferably selected from the group of allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation, inflammation of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glaucoma, retinal oedema, retinitis pigmentosa and diabetic retinopathy. The eye disorder is preferably allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation or uveitis. The method is characterized in that the administration takes place by application of the preparation of the invention to the eye.
The good systemic availability surprisingly observed on topical administration makes the pharmaceuti- cal preparations of the invention additionally suitable for systemic treatment and thus for the treatment of all other diseases which are regarded as treatable or preventable through application of PDE 4 inhibitors, especially the abovementioned diseases.
The invention therefore also relates further to the use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the systemic treatment of diseases regarded as treatable or preventable by application of PDE 4 inhibitors. Mention may preferably be made in this connection of acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondy- litis, osteoarthritis and other arthritic states).
The pharmaceutical preparations of the invention are moreover particularly suitable for adminstration to groups of patients who are suffering from the abovementioned diseases and have problems in taking pharmaceutical preparations to be administered orally, such as, for example, bedridden patients, patients in intensive medical care, patients with swallowing difficulties and children.
The invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases. The method is characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disease, with the active pharmaceutical ingredient being administered in a topical pharmaceutical preparation of the invention. The disease is preferably acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states). The method is characterized in that administration takes place by dermal administration, i.e. through application of the topical pharmaceutical preparations of the invention to the skin or mucous membranes.
The dosage forms of the invention comprise the active pharmaceutical ingredient in the dose customary for the treatment of the particular disease. The dosage of the active ingredient is of the order of magnitude customary for PDE inhibitors, it being possible to administer the daily dose in one or more dosage units. Customary dosages are disclosed for example in WO 95/01338. The normal dose on systemic therapy (oral) is between 0.001 and 3 mg per kilogram and day. Dosage forms preferred according to the invention for topical administration contain from 0.005 mg to 5 mg of roflumilast, preferably from 0.01 mg to 2.5 mg, particularly preferably 0.1 mg to 0.5 mg of roflumilast per dosage unit. Examples of pharmaceutical preparations of the invention contain 0.01 mg, 0.1 mg, 0.125 mg, 0.25 mg and 0.5 mg of roflumilast per dosage unit.

Claims

Claims
1. Topically applicable pharmaceutical preparation comprising an active pharmaceutical ingredient together with one or more pharmaceutical carriers and/or excipients suitable for topical administration, where the active pharmaceutical ingredient is a compound selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of the pyridine residue of roflumilast or salts thereof.
2. Topically applicable pharmaceutical preparation according to Claim 1 , where roflumilast is a compound of the formula I
Figure imgf000017_0001
in which
R1 is difluoromethoxy,
R2 is cyclopropylmethoxy and
R3 is 3,5-dichloropyrid-4-yl.
3. Topical pharmaceutical preparation according to Claim 1 , which is a semisolid dosage form selected from the group of ointments (e.g. solution ointment, suspension ointment), creams, gels or pastes.
4. Topical pharmaceutical preparation according to Claim 1 , which is a transdermal therapeutic system (TTS).
5. Use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the systemic treatment of diseases regarded as treatable or preventable through use of PDE 4 inhibitors.
6. Use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the treatment of disorders of the skin regarded as treatable or preventable through use of PDE 4 inhibitors.
7. Method for treating mammals, including humans, suffering from a dermatosis regarded as treatable or preventable through use of PDE 4 inhibitors, characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disorder, with the active pharmaceutical ingredient being administered in a topical pharmaceutical preparation of the invention according to Claim 1, and administration taking place by dermal administration.
8. Method according to Claim 7, where the dermatosis is psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea or other proliferative, inflammatory and allergic skin disorders.
9. Method for treating mammals, including humans, suffering from a disease regarded as treatable or preventable through use of PDE 4 inhibitors, characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is administered to the mammal with the disorder, with the active pharmaceutical ingredient being administered in a topical pharmaceutical preparation of the invention according to Claim 1 , and administration taking place by dermal administration.
10. Method according to Claim 9, where the disease is acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD) or disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states).
11. Topically applicable pharmaceutical preparation according to Claim 1 , characterized in that it is a dosage form for use on the eye.
12. Topically applicable pharmaceutical preparation according to Claim 11 , characterized in that it comprises eye drops.
13. Topically applicable pharmaceutical preparation according to Claim 11 , characterized in that it comprises a suspension of the active pharmaceutical ingredient in the carriers and/or the excipients.
14. Topically applicable pharmaceutical preparation according to Claim 11 , characterized in that it comprises an eye ointment.
15. Method for treating mammals, including humans, suffering from an eye disorder which is regarded as treatable or preventable through the use of PDE 4 inhibitors, characterized in that a therapeutically effective and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of ro- flumilast and salts thereof is administered to the mammal with the disorder, with the active pharmaceutical ingredient being administered in the topical pharmaceutical preparation of the invention according to Claim 11.
16. Method according to Claim 15, where the disease is allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation, inflammation of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glaucoma, retinal oedema, retinitis pigmentosa or diabetic retinopathy.
17. Method according to Claim 16, where allergic conjunctivitis, conjunctivitis cause by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation or uveitis is involved.
PCT/EP2003/005524 2002-03-14 2003-05-27 Topically applicable pharmaceutical preparation WO2003099334A1 (en)

Priority Applications (36)

Application Number Priority Date Filing Date Title
EA200401517A EA010416B1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation based on roflumilast and polyetheleneglycol
NZ536920A NZ536920A (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
EP08166780.0A EP2020243B1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
UA20041210683A UA81910C2 (en) 2002-05-28 2003-05-27 Topical pharmaceutical preparation
MXPA04011528A MXPA04011528A (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation.
DK03755048T DK1511516T3 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical composition
NZ537308A NZ537308A (en) 2002-05-28 2003-05-27 Ophthalmological use of roflumilast for the treatment of diseases of the eye
MEP-854/08A ME00565A (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
JP2004506857A JP5652983B2 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical formulation
CN038124068A CN1655823B (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
AU2003232828A AU2003232828B2 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
US10/515,698 US20060084684A1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
YUP-1014/04A RS51104B (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
CA2486917A CA2486917C (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation containing roflumilast
KR10-2004-7019272A KR20050014844A (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
BR0311339-6A BR0311339A (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
UAA200712909A UA88523C2 (en) 2002-05-28 2003-05-27 Dosage form of roflumilast for topical administration
DE60325354T DE60325354D1 (en) 2002-05-28 2003-05-27 TOPIC APPLICABLE PHARMACEUTICAL PREPARATION
ES03730122T ES2354971T3 (en) 2002-05-28 2003-05-27 ROFLUMILAST OPHTHALMOLOGICAL USE FOR THE TREATMENT OF EYE DISEASES.
EP03755048A EP1511516B1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
BR0311337-0A BR0311337A (en) 2002-05-28 2003-05-27 Ophthalmic use of roflumilast for the treatment of eye diseases.
KR1020117025130A KR101307093B1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
SI200331532T SI1511516T1 (en) 2002-05-28 2003-05-27 Topically applicable pharmaceutical preparation
IL164935A IL164935A (en) 2002-05-28 2004-10-31 Topically applicable pharmaceutical compositions containing a benzamide derivative
NO20045506A NO334882B1 (en) 2002-05-28 2004-12-16 Use of Roflumilast in the Preparation of Topically Applicable Pharmaceutical Preparation
IS7612A IS2639B (en) 2002-05-28 2004-12-23 Topical formulations
HRP20041211AA HRP20041211B1 (en) 2002-05-28 2004-12-27 Topically applicable pharmaceutical preparation
HK05111481.8A HK1079437A1 (en) 2002-05-28 2005-12-14 Topically applicable pharmaceutical preparation
US12/149,250 US20080280958A1 (en) 2002-05-28 2008-04-29 Topically applicable pharmaceutical preparation
CY20091100273T CY1110312T1 (en) 2002-05-28 2009-03-10 LOCALLY APPLIED PHARMACEUTICAL PREPARATION
IL209657A IL209657A0 (en) 2002-05-28 2010-11-30 Topically applicable pharmaceutical compositions containing a roflumilast
US13/219,056 US20110313005A1 (en) 2002-05-28 2011-08-26 Topically applicable pharmaceutical preparation
US14/075,035 US20140303215A1 (en) 2002-05-28 2013-11-08 Topically applicable pharmaceutical preparation
US16/150,759 US20190029956A1 (en) 2002-03-14 2018-10-03 Topically applicable pharmaceutical preparation
CY181101093T CY1121133T1 (en) 2002-05-28 2018-10-24 LOCALLY APPLICABLE PHARMACEUTICAL PREPARATION
US16/891,823 US20210116207A1 (en) 2002-05-28 2020-06-03 Topically applicable pharmaceutical preparation

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP02011830.3 2002-05-28
DE10223828 2002-05-28
DE10223828.6 2002-05-28
EP02011830 2002-05-28
DE10311613 2003-03-14
DE10311613.3 2003-03-14

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US10/515,698 A-371-Of-International US20060084684A1 (en) 2002-03-14 2003-05-27 Topically applicable pharmaceutical preparation
US12/149,250 Division US20080280958A1 (en) 2002-03-14 2008-04-29 Topically applicable pharmaceutical preparation
US13/219,056 Continuation US20110313005A1 (en) 2002-05-28 2011-08-26 Topically applicable pharmaceutical preparation

Publications (1)

Publication Number Publication Date
WO2003099334A1 true WO2003099334A1 (en) 2003-12-04

Family

ID=29587313

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2003/005524 WO2003099334A1 (en) 2002-03-14 2003-05-27 Topically applicable pharmaceutical preparation
PCT/EP2003/005536 WO2003099278A1 (en) 2002-05-28 2003-05-27 Ophthalmological use of roflumilast for the treatment of diseases of the eye

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/005536 WO2003099278A1 (en) 2002-05-28 2003-05-27 Ophthalmological use of roflumilast for the treatment of diseases of the eye

Country Status (33)

Country Link
US (7) US20060084685A1 (en)
EP (3) EP1511516B1 (en)
JP (3) JP5652983B2 (en)
KR (2) KR20050014844A (en)
CN (3) CN101491520B (en)
AT (2) ATE485821T1 (en)
AU (2) AU2003240719B2 (en)
BR (2) BR0311337A (en)
CA (2) CA2486917C (en)
CY (2) CY1110312T1 (en)
DE (2) DE60334692D1 (en)
DK (3) DK1511516T3 (en)
EA (2) EA010416B1 (en)
ES (3) ES2319517T3 (en)
HK (2) HK1079437A1 (en)
HR (1) HRP20041211B1 (en)
HU (1) HUE039709T2 (en)
IL (3) IL164935A (en)
IS (1) IS2639B (en)
LT (1) LT2020243T (en)
MA (1) MA27813A1 (en)
ME (1) ME00565A (en)
MX (2) MXPA04011528A (en)
NO (2) NO334882B1 (en)
NZ (3) NZ536920A (en)
PL (3) PL397021A1 (en)
PT (3) PT1511481E (en)
RS (1) RS51104B (en)
SI (2) SI2020243T1 (en)
TR (1) TR201815573T4 (en)
UA (2) UA88523C2 (en)
WO (2) WO2003099334A1 (en)
ZA (2) ZA200408649B (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080967A1 (en) 2003-03-10 2004-09-23 Altana Pharma Ag Novel process for the preparation of roflumilast
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
DE102004046235A1 (en) * 2004-09-22 2006-03-30 Altana Pharma Ag drug preparation
WO2006032676A1 (en) * 2004-09-22 2006-03-30 Altana Pharma Ag Pharmaceutical composition comprising roflumilast or the n-oxide of roflumilast
US7026296B2 (en) 2002-09-20 2006-04-11 Alcon, Inc. Methods of treating dry eye disorders
WO2006132342A1 (en) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. Eye drop containing roflumilast
JP2008532974A (en) * 2005-03-08 2008-08-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Roflumilast for the treatment of diabetes mellitus
US7951397B2 (en) 2002-02-20 2011-05-31 Nycomed Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US9387195B2 (en) 2011-03-07 2016-07-12 Celgene Corporation Methods for treating diseases using isoindoline compounds
CN106573889A (en) * 2014-10-24 2017-04-19 久光制药株式会社 Prodrug
US10058539B2 (en) 2012-11-08 2018-08-28 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
US20220211730A1 (en) * 2020-05-07 2022-07-07 Arcutis Biotherapeutics, Inc. Treatment of skin conditions using high krafft temperature anionic surfactants
US11992480B2 (en) 2018-11-16 2024-05-28 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12005052B2 (en) 2017-06-07 2024-06-11 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half-life
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12016848B2 (en) 2017-06-07 2024-06-25 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042558B2 (en) 2018-06-04 2024-07-23 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1511481E (en) * 2002-05-28 2011-01-14 Nycomed Gmbh Ophthalmological use of roflumilast for the treatment of diseases of the eye
FR2851247B1 (en) 2003-02-19 2007-06-29 Exonhit Therapeutics Sa METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DEGENERATIVE PATHOLOGIES
CA2552524A1 (en) * 2004-01-10 2005-07-28 Biolipid, Inc. Lipid compositions and methods of use
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
CN101389612B (en) 2006-02-21 2011-09-21 卫材R&D管理有限公司 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
EP2123641A4 (en) 2007-02-16 2011-06-22 Eisai R&D Man Co Ltd Crystal, amorphous form and salt of methyl n-ý3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl¨terephthalamic acid
CN101687820B (en) 2007-08-17 2012-07-25 卫材R&D管理有限公司 Method for producing quinazoline derivative
KR20100042246A (en) 2007-08-17 2010-04-23 에자이 알앤드디 매니지먼트 가부시키가이샤 Novel preparation for external use
CA2778229A1 (en) 2009-10-30 2011-05-19 Nestec S.A. Methods for maintaining eye health and ameliorating ophthalmic maladies in canines
ES2408132B1 (en) * 2010-09-08 2014-04-04 Universidad Miguel Hernández De Elche PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF THE EPIPHORE.
ES2377785B2 (en) 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche PHARMACEUTICAL COMPOSITION FOR DRY EYE TREATMENT.
CN102793684B (en) * 2011-05-26 2016-02-17 杭州赛利药物研究所有限公司 Roflumilast liquid preparation and preparation method thereof
US20140296301A1 (en) * 2011-06-28 2014-10-02 Bayer Pharma Aktiengesellschaft Topical ophthalmological pharmaceutical composition containing regoragenib
US9951335B2 (en) * 2012-04-10 2018-04-24 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of CYLD
CN103570610B (en) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 A kind of preparation method of roflumilast particle
CN105434328A (en) * 2014-09-01 2016-03-30 天津药物研究院有限公司 Roflumilast solid dispersion-containing solid preparation and preparation method thereof
CN104997959A (en) * 2015-08-21 2015-10-28 蔡宇平 Traditional Chinese medicine for treating chalazion
CN106148528B (en) * 2016-07-11 2019-10-01 赵晨 A kind of pathogenic mutation and its detection reagent of heredity Usher syndrome
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
CN108283620A (en) * 2018-03-13 2018-07-17 兆科药业（广州）有限公司 A kind of local medicine composition of inhibitors of phosphodiesterase-4 and preparation method thereof
KR102117525B1 (en) * 2018-07-09 2020-06-01 건양대학교 산학협력단 Pharmaceutical Composition for Preventing or Treating Chronic Rhinosinusitis Comprising PDE4B Inhibitor
CN115551478A (en) 2020-01-31 2022-12-30 阿尔库缇斯生物疗法股份有限公司 Topical formulation of roflumilast with improved delivery and plasma half-life
WO2022169615A1 (en) 2021-02-05 2022-08-11 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
CN116867480A (en) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 Methods of ocular delivery of roflumilast
WO2022173923A1 (en) * 2021-02-10 2022-08-18 Iolyx Therapeutics, Inc. Methods for ophthalmic delivery of roflumilast
KR20240039092A (en) * 2021-06-01 2024-03-26 아이디어 바이오, 엘엘씨 Extended release drug delivery systems and methods of use for ocular drugs
EP4405048A1 (en) * 2021-09-22 2024-07-31 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
WO2024058848A1 (en) 2022-09-15 2024-03-21 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
WO1995001338A1 (en) * 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
WO2000018388A2 (en) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
WO2001032165A1 (en) * 1999-10-29 2001-05-10 Smithkline Beecham Corporation Method for administering a phosphodiesterase 4 inhibitor
WO2002038155A1 (en) * 2000-11-07 2002-05-16 Merck & Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891904A (en) * 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
KR960703621A (en) * 1993-08-10 1996-08-31 후지야마 아키라 Percutaneously absorbable preparation
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
BR9914399A (en) * 1998-09-29 2002-01-22 Fujisawa Pharmaceutical Co Pyridopyrazine compound, process for its production and use
US20020006418A1 (en) * 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
WO2000053182A2 (en) 1999-03-10 2000-09-14 Byk Gulden Lomberg Chemische Fabrik Gmbh 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
IL150486A0 (en) * 2000-01-31 2002-12-01 Pfizer Prod Inc Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
JP2004502643A (en) * 2000-02-16 2004-01-29 ユニバーシティ・オブ・ネブラスカ・メディカル・センター Methods and compositions for treating fibrotic diseases
EP1289961A1 (en) * 2000-05-25 2003-03-12 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) * 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) * 2001-11-09 2003-05-15 Johannes Barsig Combination
PT1511481E (en) * 2002-05-28 2011-01-14 Nycomed Gmbh Ophthalmological use of roflumilast for the treatment of diseases of the eye

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) * 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5011843A (en) * 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
WO1995001338A1 (en) * 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
WO2000018388A2 (en) * 1998-09-30 2000-04-06 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
WO2001032165A1 (en) * 1999-10-29 2001-05-10 Smithkline Beecham Corporation Method for administering a phosphodiesterase 4 inhibitor
WO2002038155A1 (en) * 2000-11-07 2002-05-16 Merck & Co., Inc. Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REID P: "ROFLUMILAST", CURRENT OPINION IN INVESTIGATIONAL DRUGS, CURRENT DRUGS, LONDON, GB, vol. 3, no. 8, August 2002 (2002-08-01), pages 1165 - 1170, XP001119630, ISSN: 0967-8298 *

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US9468598B2 (en) 2002-02-20 2016-10-18 Astrazeneca Ab Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US8431154B2 (en) 2002-02-20 2013-04-30 Takeda Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
US7951397B2 (en) 2002-02-20 2011-05-31 Nycomed Gmbh Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
US7026296B2 (en) 2002-09-20 2006-04-11 Alcon, Inc. Methods of treating dry eye disorders
US8536206B2 (en) 2003-03-08 2013-09-17 Takeda Gmbh Process for the preparation of roflumilast
US7470791B2 (en) 2003-03-10 2008-12-30 Nycomed Gmbh Process for the preparation of roflumilast
WO2004080967A1 (en) 2003-03-10 2004-09-23 Altana Pharma Ag Novel process for the preparation of roflumilast
DE102004046236A1 (en) * 2004-09-22 2006-03-30 Altana Pharma Ag drug preparation
JP2008513416A (en) * 2004-09-22 2008-05-01 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Aqueous pharmaceutical preparations containing roflumilast
WO2006032676A1 (en) * 2004-09-22 2006-03-30 Altana Pharma Ag Pharmaceutical composition comprising roflumilast or the n-oxide of roflumilast
DE102004046235A1 (en) * 2004-09-22 2006-03-30 Altana Pharma Ag drug preparation
US9205044B2 (en) 2004-09-22 2015-12-08 Takeda Gmbh Aqueous pharmaceutical preparation comprising roflumilast
JP2008532974A (en) * 2005-03-08 2008-08-21 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Roflumilast for the treatment of diabetes mellitus
US8541456B2 (en) 2005-03-08 2013-09-24 Takeda Gmbh Roflumilast for the treatment of diabetes mellitus type 2
WO2006132342A1 (en) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. Eye drop containing roflumilast
US9387195B2 (en) 2011-03-07 2016-07-12 Celgene Corporation Methods for treating diseases using isoindoline compounds
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
US10058539B2 (en) 2012-11-08 2018-08-28 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
US10413532B2 (en) 2012-11-08 2019-09-17 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
US11065236B2 (en) 2012-11-08 2021-07-20 Rhizen Pharmaceuticals Sa Pharmaceutical compositions containing a PDE4 inhibitor and a PI3 delta or dual PI3 delta-gamma kinase inhibitor
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
CN106573889A (en) * 2014-10-24 2017-04-19 久光制药株式会社 Prodrug
CN106573889B (en) * 2014-10-24 2019-01-01 久光制药株式会社 prodrug
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12005052B2 (en) 2017-06-07 2024-06-11 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half-life
US12016848B2 (en) 2017-06-07 2024-06-25 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US12042558B2 (en) 2018-06-04 2024-07-23 Arcutis Biotherapeutics, Inc. Method and formulation for improving roflumilast skin penetration lag time
US11992480B2 (en) 2018-11-16 2024-05-28 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20220211730A1 (en) * 2020-05-07 2022-07-07 Arcutis Biotherapeutics, Inc. Treatment of skin conditions using high krafft temperature anionic surfactants

Also Published As

Publication number Publication date
MA27813A1 (en) 2006-04-03
UA88523C2 (en) 2009-10-26
IS7612A (en) 2004-12-23
US20110313005A1 (en) 2011-12-22
EP2020243A1 (en) 2009-02-04
CN1655823A (en) 2005-08-17
PL372082A1 (en) 2005-07-11
EP1511481A1 (en) 2005-03-09
CN101491520A (en) 2009-07-29
TR201815573T4 (en) 2018-11-21
LT2020243T (en) 2018-11-12
JP5652983B2 (en) 2015-01-14
ES2319517T3 (en) 2009-05-08
JP2012229245A (en) 2012-11-22
HRP20041211A2 (en) 2006-04-30
HK1079437A1 (en) 2006-04-07
RS51104B (en) 2010-10-31
CY1110312T1 (en) 2015-01-14
ES2354971T3 (en) 2011-03-21
SI2020243T1 (en) 2018-11-30
US20080280958A1 (en) 2008-11-13
PT1511481E (en) 2011-01-14
AU2003232828A1 (en) 2003-12-12
EP1511516B1 (en) 2008-12-17
PT2020243T (en) 2018-11-09
EP1511516A1 (en) 2005-03-09
EA020569B1 (en) 2014-12-30
KR20050014844A (en) 2005-02-07
CA2486910C (en) 2011-11-29
BR0311339A (en) 2005-03-22
US20140303215A1 (en) 2014-10-09
NO334882B1 (en) 2014-06-30
HUE039709T2 (en) 2019-01-28
US20210116207A1 (en) 2021-04-22
AU2003232828B2 (en) 2010-06-24
MXPA04011612A (en) 2005-03-07
NO20045506L (en) 2004-12-16
AU2003240719B2 (en) 2009-12-10
EA200702588A1 (en) 2008-08-29
CN1655782A (en) 2005-08-17
EP2020243B1 (en) 2018-08-15
NO20045656L (en) 2004-12-27
US20190029956A1 (en) 2019-01-31
DE60325354D1 (en) 2009-01-29
IL165065A (en) 2010-11-30
HRP20041211B1 (en) 2013-06-30
HK1079445A1 (en) 2006-04-07
CN101491520B (en) 2011-03-16
IL209657A0 (en) 2011-02-28
BR0311337A (en) 2005-03-15
PL372095A1 (en) 2005-07-11
ME00565A (en) 2011-12-20
ATE417628T1 (en) 2009-01-15
NZ553731A (en) 2007-07-27
EP1511481B1 (en) 2010-10-27
JP2005529930A (en) 2005-10-06
PL211870B1 (en) 2012-07-31
EA010416B1 (en) 2008-08-29
DK1511516T3 (en) 2009-04-06
ATE485821T1 (en) 2010-11-15
AU2003240719A1 (en) 2003-12-12
EA200401517A1 (en) 2005-06-30
RS101404A (en) 2007-02-05
IS2639B (en) 2010-06-15
IL164935A (en) 2010-12-30
ZA200409584B (en) 2006-05-31
ES2693094T3 (en) 2018-12-07
ZA200408649B (en) 2007-12-27
PL212134B1 (en) 2012-08-31
PT1511516E (en) 2009-02-20
US20060084684A1 (en) 2006-04-20
NZ536920A (en) 2007-04-27
NZ537308A (en) 2009-09-25
PL397021A1 (en) 2012-03-26
IL164935A0 (en) 2005-12-18
CN100490804C (en) 2009-05-27
DK1511481T3 (en) 2011-01-24
CA2486917C (en) 2011-11-22
KR101307093B1 (en) 2013-09-11
CN1655823B (en) 2010-05-26
DE60334692D1 (en) 2010-12-09
CA2486910A1 (en) 2003-12-04
DK2020243T3 (en) 2018-11-19
UA81910C2 (en) 2008-02-25
US20060084685A1 (en) 2006-04-20
NO334916B1 (en) 2014-07-14
CY1121133T1 (en) 2019-12-11
KR20110122230A (en) 2011-11-09
JP5683538B2 (en) 2015-03-11
SI1511516T1 (en) 2009-06-30
MXPA04011528A (en) 2005-02-14
CA2486917A1 (en) 2003-12-04
IL165065A0 (en) 2005-12-18
WO2003099278A1 (en) 2003-12-04
JP2005529928A (en) 2005-10-06

Similar Documents

Publication Publication Date Title
US20210116207A1 (en) Topically applicable pharmaceutical preparation
EP2214644B1 (en) Water-immiscible materials as vehicles for drug delivery
JP5135441B2 (en) Tacrolimus external preparation
JP4308255B2 (en) Ophthalmic transdermal preparation containing a muscarinic receptor agonist
WO1999007355A1 (en) Idebenone-containing preparation for percutaneous administration
WO2005053672A1 (en) Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient
JP2004051522A (en) External preparation for treating skin disease and itch caused by hemodialysis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-1014/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AU BA BR CA CN CO CU DZ EC GE HR ID IL IN IS JP KR LT LV MA MK MX NO NZ PH PL SG TN UA US VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 594/MUMNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003755048

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/A/2004/011528

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2486917

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004/09584

Country of ref document: ZA

Ref document number: 2004506857

Country of ref document: JP

Ref document number: 1-2004-501951

Country of ref document: PH

Ref document number: 200409584

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1020047019272

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 20038124068

Country of ref document: CN

Ref document number: 372095

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 536920

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200401517

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P20041211A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 1200401395

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020047019272

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003755048

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006084684

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10515698

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10515698

Country of ref document: US